The company received the Innovation Passport in the UK for zilebesiran, an investigational treatment of hypertension
News
Westminster Drug Project and Gilead Sciences join forces to take on hepatitis C
The companies have partnered for a second time to support sector-wide efforts to eliminate hepatitis C virus in drug and alcohol services
Bachem and Eli Lilly link up to advance oligonucleotide products
The agreement will see the two companies expand current oligonucleotide technologies
Vertex trial for hypoglycaemia therapy shows early promise
New data now reveals significant increases in the blood glucose time-in-range compared to baseline, following VX-880 dosage
2022 Marketer of the Year competition has launched!
Celebrating and uncovering exceptional pharma marketing talent for nearly three decades, the 2022 Marketer of the Year competition has launched!
The PharmaTimes Communications Awards are back for 2022!
Unique to the industry, the Communications Awards gives the opportunity for communications professionals to demonstrate their leadership, creativity, and teamwork skills in a variety of fun and engaging virtual challenges.
Daiichi Sankyo and AstraZeneca’s Enhertu delivers promising trial results
Enhertu reduced the risk of disease progression or death compared to chemotherapy in certain patients with metastatic breast cancer
Cambridge Pharma promises to boost drug development
New facility opens on the Cambridge Research Park offering sterile finish
Teva UK introduces first generic oral anticoagulant
Apixaban will be available for the prevention of stroke and deep vein thrombosis
NICE recommends UCB’s Fintepla for Dravet syndrome
The drug is used to treat seizures caused by this rare syndrome that is a form of epilepsy
Sandoz launches new global health inequalities initiative
‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
Memo Therapeutics initiates pioneering BK virus therapy trial
Antibody addresses high unmet medical need in rapidly growing kidney transplant market
NICE approves Merck’s Keytruda for adult patients with rare triple negative breast cancer
The injection is given in combination with chemotherapy and administered once every three weeks
NRG receives £2.68m funding boost for neurodegenerative disorders
NRG Therapeutics announces multi-million Innovate UK Award to develop treatments for Parkinson’s and motor neurone disease
Thousands to potentially benefit from Roche treatment for sight loss
Faricimab is administered as an eye injection with an interval of up to 16 weeks
